Portfolio
Since 1969, we’ve been partnering with ambitious entrepreneurs to help them to scale. Meet our global portfolio, both past and present.
Acacia Pharma
Developing nausea treatments for surgical and cancer patients.
Year of investment: 2013
FP F-Prime
Accuri Cytometers
Developing cost effective cytometers for laboratories.
Year of investment: 2008 (Exited)
FP F-Prime
Adagene
Antibody discovery and engineering using proprietary Smart Antibody Technology.
Year of investment: 2011
Adaptimmune
Clinical-stage biopharma, engineered T-cell therapy modifies immune cells to detect and destroy cancer.
Year of investment: 2015
Akriveia Therapeutics
Developing the next generation of cancer immunotherapies.
Year of investment: 2018
FP F-Prime
Amphora Medical
Cystoscopic technology for the treatment of overactive bladder.
Year of investment: 2013
FP F-Prime
Apellis Pharmaceuticals
Developing novel therapeutic compounds to treat disease.
Year of investment: 2017
FP F-Prime
AppsFlyer
SaaS mobile marketing analytics and attribution platform.
Year of investment: 2015
Artemis Health
Unlocking the power of benefits data.
Year of investment: 2017
FP F-Prime
Avalyn Pharma
Advancing therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Year of investment: 2017
FP F-Prime
Avidity Nanomedicines
Biotech company pioneering Antibody Oligonucleotide Conjugates.
Year of investment: 2014
FP F-Prime
Axoni
Re-platforming global capital markets.
Year of investment: 2018
FP F-Prime
Bang Er Orthopedic Hospital Group
Private medical service provider focusing on orthopaedic care.
Year of investment: 2014
Bikam
Developing novel therapies for diseases of the eye.
Year of investment: 2007 (Exited)
FP F-Prime
Bio Connect Systems
Developing products for vascular and general surgeons.
Year of investment: 2007
FP F-Prime
Blueprint
Developing personalised, highly-selective cancer therapies.
Year of investment: 2012 (Exited)
FP F-Prime
Buoy
Symptom and cure checker that uses an intelligent algorithm to diagnose patients.
Year of investment: 2017
FP F-Prime
Cardiokine
Developing lixivaptan, an oral compound for the potential treatment of hyponatremia.
Year of investment: 2006 (Exited)
FP F-Prime
Caribou biosciences
Gene editing company.
Year of investment: 2015
FP F-Prime
Castle
Zero-configuration solution for account takeover protection.
Year of investment: 2016
Checkmate Pharmaceuticals
Developing approaches to activate the immune system to recognise and destroy tumour cells.
Year of investment: 2017
FP F-Prime
Cloudant
Distributed NoSQL database-as-a-service for developers.
Year of investment: 2012 (Exited)
FP F-Prime
Codeship
Cloud-based platform helping software developers test and deploy their code.
Year of investment: 2013 (Exited)
FP F-Prime
Coherus Biosciences
Developing and commercialising high-quality biosimilar therapeutics.
Year of investment: 2014 (Exited)
FP F-Prime
Compass Therapeutics
Comprehensively drugging the tumor-immune synapse with human antibodies.
Year of investment: 2015
FP F-Prime
Core Diagnostics
High-end diagnostics services for disease stratification and therapy selection.
Year of investment: 2016
Cygnus
Operator of multi-speciality hospitals in North India Tier 2 and Tier 3 cities.
Year of investment: 2014
Denali
Therapies for neurodegenerative diseases.
Year of investment: 2015
Devoted Health
Tech-enabled health insurance and clinical services solution.
Year of investment: 2017
FP F-Prime
Dimension Therapeutics
Develops AAV gene therapies for rare disease.
Year of investment: 2013 (Exited)
FP F-Prime
Eris Exchange
Interest rate swaps trading venue.
Year of investment: 2012
FP F-Prime
Eyebright
Ophthalmic medical device manufacturer tackling cataracts, glaucoma etc.
Year of investment: 2014
Flywire
Provider of high-ticket payment solutions.
Year of investment: 2013
FP F-Prime
Fold Rx
Creating modifying drug therapies for diseases of protein misfolding.
Year of investment: 2004 (Exited)
FP F-Prime
Hile
Animal vaccine manufacturer in China.
Year of investment: 2010
Hua
Clinical-stage drug development focused on treatment of diabetes and central nervous system conditions.
Year of investment: 2010